Stream
Stories
-
Onconic registers Phase 3 trial of JP-1366-based triple therapy for H. Pylori
The study, led by Onconic Therapeutics Inc., plans to enroll 414 participants and begin recruiting on November 1, 2026. It is a multicenter, randomized, double-blind, active-controlled Phase III trial to evaluate the efficacy and safety of JP-1366-based triple therapy in H. Pylori-positive subjects.
-
Merck registers Phase 3 trial of ensifentrine for COPD exacerbation prevention
Merck Sharp & Dohme LLC has registered a Phase 3, randomized, double-blind, placebo-controlled study (ENHANCE-3) to evaluate ensifentrine (MK-5884) for preventing moderate and severe COPD exacerbations. The trial plans to enroll 2136 participants, begin on October 23, 2026, and reach primary completion on April 29, 2029.
-
EMA recommends authorization of Rasonque for metastatic pancreatic cancer
EMA's CHMP has recommended granting a marketing authorization for Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior treatment. The recommendation follows a phased review that shortened assessment to less than 150 days, with Rasonque showing a median overall survival of 12.4 months versus 6.7 months for chemotherapy in a phase 3 study of 500 patients.
-
Sanofi posts results of Phase 3 itepekimab trial in COPD
The Phase 3 study, NCT04701983 (AERIFY-1), enrolled 1127 participants and completed primary data collection on April 11, 2025. Results were first posted on ClinicalTrials.gov on October 15, 2026.
-
United Therapeutics posts results of Phase 3 TETON-2 inhaled treprostinil study
The study enrolled 597 participants and completed primary data collection on June 30, 2025. Results were first posted on ClinicalTrials.gov on October 15, 2026.
-
ACADIA posts results of Phase 3 carbetocin nasal spray trial in Prader-Willi syndrome
The study, completed in August 2025, enrolled 175 participants and evaluated carbetocin nasal spray versus placebo over 12 weeks. Results were first posted on ClinicalTrials.gov on October 15, 2026.
-
Vertex posts results of Phase 3 ELX/TEZ/IVA study in infants
Vertex Pharmaceuticals Incorporated posted results of a completed Phase 3, open-label study evaluating the pharmacokinetics, safety, tolerability, pharmacodynamics, and efficacy of ELX/TEZ/IVA in cystic fibrosis participants 12 to less than 24 months of age. The study enrolled 67 participants and began on June 27, 2023, with primary completion on September 4, 2025.
-
CHMP adopts positive opinion on Rasonque for metastatic pancreatic cancer
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 15 October 2026, recommending marketing authorization for Rasonque, a daraxonrasib monotherapy for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The product will be available as 100 mg and 150 mg film-coated tablets and is designated as an orphan medicine.
-
FDA authorizes emergency use of four animal drugs for New World screwworm
The FDA issued four Emergency Use Authorizations for products requested by Elanco US Inc., Zoetis Inc., Bimeda Animal Health Ltd., and Sergeant's Pet Care Products LLC to prevent infestations caused by New World screwworm larvae in various animals. The authorizations follow a HHS determination on August 18, 2025 that circumstances justify emergency use.
-
FDA launches Rare Disease Framework Initiative to gather public feedback
The FDA announced the Rare Disease Framework Initiative on October 14, 2026, aiming to create a fit-for-purpose framework for rare disease drug development. It will host an October 28 meeting at its White Oak campus to solicit feedback from patients, advocates, and industry.
-
FDA approves expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive NMIBC
On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, adding high-grade papillary-only tumors to the prior indication for carcinoma in situ. The approval is based on efficacy data from Cohort A of QUILT-3.032, which showed a 62% complete response rate (95% CI: 51, 73).
-
Almirall registers Phase 3b trial of lebrikizumab in face and neck atopic dermatitis
The study plans to enroll 230 participants and is expected to start in November 2026. It aims to evaluate the efficacy and safety of lebrikizumab for up to 32 weeks in adults and adolescents with moderate-to-severe face and neck atopic dermatitis who also have moderate-to-severe AD elsewhere and need systemic therapy.